Key result
Oral PCSK9 inhibitors lower LDL-C up to ~62% vs placebo in meta-analysis.
Why the study?
Oral PCSK9 inhibitors are a promising alternative to injectable therapies for dyslipidemia, but their comparative efficacy and safety across different dosing regimens had not been systematically evaluated.
Do oral PCSK9 inhibitors across different dosing regimens reduce LDL-C levels and improve lipid parameters compared with placebo in patients with dyslipidemia?
Meta-Analysis (n=4,227)
Do oral PCSK9 inhibitors across different dosing regimens reduce LDL-C levels and improve lipid parameters compared with placebo in patients with dyslipidemia?
Oral PCSK9 inhibitors demonstrate ~60% reductions in LDL-C and high rates of LDL-C target attainment with a favorable safety profile, supporting their potential as oral alternatives to injectable PCSK9 therapies in dyslipidemia.
Answers are grounded in this paper and cite their sources.
Oral PCSK9 inhibitors may serve as convenient alternatives to injectables for LDL-C lowering; extends RCT evidence to oral formulations in dyslipidemia.
Background: Despite the availability of several lipid-lowering therapies, achieving optimal cholesterol control remains challenging in many patients with dyslipidemia. Although injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors provide substantial reductions in low-density lipoprotein cholesterol (LDL-C), their use may be limited by administration-related challenges and patient acceptance. Recently developed oral PCSK9 inhibitors represent a promising alternative; however, their comparative efficacy and safety across different dosing regimens have not been systematically evaluated. Methods: A comprehensive literature search was performed in PubMed, Scopus, the Cochrane Library, and Web of Science from database inception through March 31, 2026, to identify eligible randomized controlled trials (RCTs). Risk of bias was assessed using the ROB-2 tool, and all analyses were conducted in R. The primary outcome was the mean percentage change from baseline in LDL-C levels. Secondary outcomes included the mean percentage change from baseline in non–high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, apolipoprotein B, and safety outcomes. Results: Five RCTs comprising 4,227 participants met the inclusion criteria. In the dose-stratified network meta-analysis, NNC0385-0434 100 mg produced the greatest reduction in LDL-C compared with placebo (MD = –61.80%, 95% CI [–78.10, –45.50]; SUCRA = 0.85), followed closely by MK-0616 30 mg (MD = –60.90%, 95% CI [–74.98, –46.82]; SUCRA = 0.84), MK-0616 18 mg (SUCRA = 0.80), and MK-0616 20 mg (SUCRA = 0.79). Significant dose-dependent reductions were also observed in non-HDL-C, total cholesterol, lipoprotein(a), and apolipoprotein B. In addition, MK-0616 20 mg and NNC0385-0434 100 mg significantly increased HDL-C. Oral PCSK9 inhibitors markedly improved LDL-C goal attainment, with MK-0616 20 mg ranking highest (RR = 45.07, 95% CI [27.70, 73.35]). Furthermore, these agents did not increase the risk of adverse events and were associated with a lower incidence of fatigue. Conclusion: Oral PCSK9 inhibitors provide substantial lipid-lowering efficacy, significantly improve LDL-C target achievement, and demonstrate a favorable safety profile compared with placebo. These findings support their potential role as effective oral alternatives for the management of dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Talkhan et al. (2026) conducted a meta-analysis in Dyslipidemia (n=4,227). Oral PCSK9 inhibitors (NNC0385-0434, MK-0616) vs. Placebo was evaluated on Mean percentage change from baseline in LDL-C levels (MD -61.80%, 95% CI -78.10 to -45.50). Oral PCSK9 inhibitors significantly reduced LDL-C vs placebo, led by NNC0385-0434 100 mg (MD -61.80%, 95% CI -78.10 to -45.50) and MK-0616 30 mg (MD -60.90%, 95% CI -74.98 to -46.82).
Synapse has enriched 10 related papers. Consider them for comparative context: